Minneapolis Veterans Affairs Health Care System

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Monday, November 6, 2023

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

Cala kIQ™ System to Treat Hand Tremor Named to TIME'S List of the Best Inventions of 2023

Retrieved on: 
Wednesday, October 25, 2023

SAN MATEO, Calif., Oct. 25, 2023 /PRNewswire/ -- Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, was named in TIME's Best Inventions of 2023 for the Cala kIQ™ System which delivers effective therapy for action hand tremor in adults with essential tremor and Parkinson's disease.

Key Points: 
  • SAN MATEO, Calif., Oct. 25, 2023 /PRNewswire/ -- Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, was named in TIME's Best Inventions of 2023 for the Cala kIQ™ System which delivers effective therapy for action hand tremor in adults with essential tremor and Parkinson's disease.
  • TIME reveals its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives.
  • The Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries.
  • Cala is working to secure additional coverage and reimbursement for the new Parkinson's disease indication for the Cala kIQ System.

America's Veterans Deserve High Quality Anesthesia Care

Retrieved on: 
Wednesday, September 20, 2023

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- During Congressional testimony today, the American Association of Nurse Anesthesiology (AANA) urged the Veterans Affairs (VA) healthcare system to provide the same anesthesia care and services to our veterans as is in place in healthcare systems in 49 states. AANA President-Elect Jan Setnor, MSN, CRNA, Col. (Ret), USAFR, NC, in testimony before the House VA Committee Subcommittee on Health, defended Certified Registered Nurse Anesthetists' (CRNAs') ability to deliver high-quality anesthesia care to all populations, including the complex needs of our nation's veterans, as a result of their specialized and detailed anesthesia training.

Key Points: 
  • Setnor stressed the need to allow CRNAs to apply this extensive training in delivering healthcare to our nation's veterans.
  • The men and women who have selflessly served our nation deserve the highest quality of care and all scientific evidence and multiple independent groups have concluded that that is CRNA care."
  • This decreases wait times, increases access to quality care and improves patient safety and satisfaction.
  • All anesthesia providers do high acuity/complex cases and take call independent of each other.

Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023

The Company incurred non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023.

Key Points: 
  • The Company incurred non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023.
  • Financial Results for the Second Quarter Ended June 30, 2023
    The Company reported revenue of $113,000 for the second quarter 2023, compared to $185,000 for the same period last year.
  • The Company reported $8.5 million in cash and cash equivalents as of June 30, 2023.
  • The Company believes that its cash and cash equivalents as of June 30, 2023 will be sufficient to allow the Company to fund its commercial, R&D and corporate operations through the first quarter of 2024.

Los Angeles Center for Ear, Nose, Throat and Allergy Welcomes Laryngologist, Dr. Abie Mendelsohn to Practice

Retrieved on: 
Tuesday, August 1, 2023

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) has announced the addition of Dr. Abie Mendelsohn, M.D., F.A.C.S. to their practice. Dr. Mendelsohn is a fellowship trained laryngologist who offers a university level, minimally invasive surgical approach to head and neck surgery.

Key Points: 
  • LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- The Los Angeles Center for Ear, Nose, Throat, and Allergy (LA CENTA) has announced the addition of Dr. Abie Mendelsohn, M.D., F.A.C.S.
  • Dr. Mendelsohn is a fellowship trained laryngologist who offers a university level, minimally invasive surgical approach to head and neck surgery.
  • "We could not be more excited to welcome Dr. Mendelsohn to our practice," said LA CENTA Founder and CEO Dr. Geoff Trenkle, D.O.
  • Dr. Mendelsohn has also served as a Staff Surgeon in the Division of Head & Neck Surgery at the Veterans Affairs (VA) Medical Center of Greater Los Angeles and Volunteer Staff Surgeon at Walter Reed National Military Medical Center.

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Retrieved on: 
Wednesday, June 14, 2023

“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala.

Key Points: 
  • “At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala.
  • Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise.
  • The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief.
  • Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System.

Motus GI Announces DDW 2023 Clinical Study Presentation Showing Pure-Vu EVS Drove a 33% Hospital-Wide Improvement in Incomplete Bowel Prep Rate at Minneapolis VA Medical Center

Retrieved on: 
Thursday, May 11, 2023

The study defined IBP as a Boston Bowel Preparation Score (BBPS) of

Key Points: 
  • The study defined IBP as a Boston Bowel Preparation Score (BBPS) of
  • Pure-Vu EVS was used in 46 IBP patients during the six month Pure-Vu phase of the study.
  • Overall procedural success was achieved in 36 of 46 cases (78.3%) that used the Pure-Vu EVS.
  • The mean BBPS in successful cases improved from 4.8 at the beginning of the procedure to 8.7 after using the Pure-Vu EVS.

National Contractor and Veterans’ Organization Call on OSHA for Increased Suicide Awareness in Construction Industry at the Federal Level

Retrieved on: 
Tuesday, May 2, 2023

In a letter sent to the Occupational Safety and Health Administration (OSHA), the organizations call for additional suicide awareness and prevention initiatives, and inclusion of suicide awareness and prevention training as a core requirement in the OSHA 10 and OSHA 30 training curricula.

Key Points: 
  • In a letter sent to the Occupational Safety and Health Administration (OSHA), the organizations call for additional suicide awareness and prevention initiatives, and inclusion of suicide awareness and prevention training as a core requirement in the OSHA 10 and OSHA 30 training curricula.
  • View the full release here: https://www.businesswire.com/news/home/20230502005439/en/
    According to the Centers for Disease Control , the construction industry has the second highest suicide rate of any United States industry group.
  • The rate of suicide is about four times higher than the general population and is the second-highest rate of all workplace industries at 45 per 100,000.
  • “The alarming data around the prevalence of mental health disorders and suicide in the construction industry requires immediate action to better support workers,” said John Fish, Chairman and CEO of Suffolk.

New Fisher House Dedicated at the Columbia Veterans Affairs Health Care System

Retrieved on: 
Monday, April 24, 2023

Columbia, SC, April 24, 2023 (GLOBE NEWSWIRE) -- The Columbia VA Health Care System (VAHCS) dedicated a new Fisher House at the Wm.

Key Points: 
  • Columbia, SC, April 24, 2023 (GLOBE NEWSWIRE) -- The Columbia VA Health Care System (VAHCS) dedicated a new Fisher House at the Wm.
  • “This new Columbia VA Fisher House is a beautiful addition to our 97‐acre campus.
  • The Columbia Fisher House has 16 mobility-accessible suites, a spacious kitchen, large communal living, dining and family rooms, laundry room and a shared patio.
  • The home was gifted to VA upon completion as part of the public‐private partnership between Fisher House Foundation and the Department of Veterans Affairs.

FDA Grants Lenire® Tinnitus Treatment Device De Novo Approval

Retrieved on: 
Tuesday, March 7, 2023

CHICAGO, March 7, 2023 /PRNewswire/ -- Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.

Key Points: 
  • CHICAGO, March 7, 2023 /PRNewswire/ -- Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.
  • The De Novo approval of Lenire is significant as it acknowledges Lenire as a technological and clinical pioneer for tinnitus treatment.
  • "With this FDA approval of the Lenire device, it will provide me and tinnitus specialists across the United States with an exciting new tinnitus treatment option for our clinical toolbox," explained Dr. Jason Leyendecker (AuD).
  • "FDA approval of the Lenire Tinnitus Treatment System is a quantum leap forward in the caring of patients with bothersome tinnitus.